DrugPatentWatch Database Preview

TECHNIVIE Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has three hundred and sixty patent family members in forty-five countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

Summary for TECHNIVIE

International Patents:	360
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	1
Clinical Trials:	2
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE
DailyMed Link:	TECHNIVIE at DailyMed

Generic Entry Opportunity Date for TECHNIVIE

NDA:

207931

Dosage::

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes					Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes			Y	Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		RX	Yes	Yes

  Purchase this report

see a sample report or, see our see our flat-rate plans

Expired US Patents for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015

Non-Orange Book US Patents for TECHNIVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,676,797	Anti-viral compounds
8,674,112	Polymorph of a pharmaceutical
8,716,454	Solid compositions
9,255,092	Polymorph of a pharmaceutical

  Purchase this report

see a sample report or, see our see our flat-rate plans

International Patents for TECHNIVIE

Country	Document Number	Estimated Expiration
Spain	2526908
Mexico	346264
Japan	5530514
Cyprus	1116748

Supplementary Protection Certificates for TECHNIVIE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015011	Lithuania		PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
2015000042	Germany		PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
7 50010-2015	Slovakia		PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
0150019 00156	Estonia		PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015